Kura Oncology, Inc. (KURA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 8M 16M 24M Q1 '25: 14.1M Q2 '25: 15.3M Q3 '25: 20.8M Q4 '25: 17.3M Q1 '26: 18.3M Q2 '26: 20.9M Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

0 8M 16M 24M Q1 '26: 18M Q2 '26: 20.6M Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '12: -4.7K Q4 '12: -8.4K Q1 '13: -4.7K Q2 '13: -5.5K Q3 '13: -4.5K Q4 '13: -8.1K Q1 '14: -4.1K Q2 '14: -5.2K Q3 '14: -4.8K Q4 '14: -9.8K Q1 '24: -54.5M Q2 '24: -56.4M Q3 '24: -59.9M Q4 '24: -22.5M Q1 '25: -64.7M Q2 '25: -72.7M Q3 '25: -80M Q4 '25: -86.3M Q1 '26: -78.8M Q2 '26: -73M Q4 '12 Q3 '13 Q2 '14 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -33.4M Q4 '21: -32.7M Q1 '22: -32.5M Q2 '22: -34.8M Q3 '22: -35.5M Q4 '22: -33.1M Q1 '23: -34.1M Q2 '23: -37.2M Q3 '23: -38.6M Q4 '23: -42.8M Q1 '24: -49.5M Q2 '24: -50.8M Q3 '24: -54.4M Q4 '24: -19.2M Q1 '25: -57.4M Q2 '25: -66.1M Q3 '25: -74.1M Q4 '25: -81M Q1 '26: -73.3M Q2 '26: -68.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 90K 180K 270K Q1 '26: 262K Q2 '26: 243K Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-100M 0 100M 200M 300M Q3 '21: -24.6M Q4 '21: -23.4M Q1 '22: -32.2M Q2 '22: -30.3M Q3 '22: -21M Q4 '22: -26.5M Q1 '23: -35.9M Q2 '23: -25.6M Q3 '23: -29M Q4 '23: -34.3M Q1 '24: -48.8M Q2 '24: -42.5M Q3 '24: -43.4M Q4 '24: 269.1M Q1 '25: -71.9M Q2 '25: -28.8M Q3 '25: -80.6M Q4 '25: 117.3M Q1 '26: -85.9M Q2 '26: -62.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-100M 0 100M 200M 300M Q3 '21: -25.3M Q4 '21: -23.5M Q1 '22: -32.2M Q2 '22: -30.5M Q3 '22: -21.4M Q4 '22: -26.5M Q1 '23: -35.9M Q2 '23: -25.7M Q3 '23: -29M Q4 '23: -34.3M Q1 '24: -48.9M Q2 '24: -42.5M Q3 '24: -43.4M Q4 '24: 268.8M Q1 '25: -72.2M Q2 '25: -30.2M Q3 '25: -83.2M Q4 '25: 115M Q1 '26: -86M Q2 '26: -63.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '21: 66.3M Q3 '21: 66.4M Q1 '22: 66.6M Q2 '22: 66.7M Q3 '22: 66.9M Q1 '23: 68.4M Q2 '23: 69.8M Q3 '23: 77.2M Q1 '24: 83.9M Q2 '24: 86.6M Q3 '24: 87M Q1 '25: 87.4M Q2 '25: 87.6M Q3 '25: 87.6M Q1 '26: 88.6M Q2 '26: 88.9M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '21: -1.92 Q4 '21: -1.97 Q1 '22: -2.00 Q2 '22: -2.01 Q3 '22: -2.04 Q4 '22: -2.03 Q1 '23: -2.04 Q2 '23: -2.05 Q3 '23: -2.02 Q4 '23: -2.08 Q1 '24: -2.17 Q2 '24: -2.23 Q3 '24: -2.36 Q4 '24: -2.03 Q1 '25: -2.10 Q2 '25: -2.26 Q3 '25: -2.48 Q4 '25: -3.18 Q1 '26: -3.35 Q2 '26: -3.37 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.